Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicity
Authors:
- 1 December 2008
- journal article
- clinical trial
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 13 (4) , 267-274
Abstract
Abstract We investigated a series of bortezomib‐treated patients and correlated the course of bortezomib‐induced peripheral neurotoxicity with the presence or absence of peripheral neuropathy at baseline. Forty‐eight patients were examined with the total neuropathy score reduced version (TNSr), visual analogue score (VAS) for pain, and nerve conduction studies at baseline and after two and four cycles of chemotherapy. Twenty‐three patients had a baseline TNSr = 0–2, and 25 patients had a baseline TNSr >2 (median = 6, range 3–13). The course of bortezomib‐induced peripheral neurotoxicity was generally more severe in those patients with the highest baseline TNSr. However, among those subjects with a normal baseline TNSr, two patients developed a clinically relevant peripheral neuropathy with a marked increase in TNSr as early as after two cycles of bortezomib treatment (TNSr = 10 and 15, respectively), while after four cycles, three other patients with normal baseline TNSr had a TNSr of 11, 12, and 13. VAS reporting confirmed that painful neuropathy is frequent after bortezomib administration. Our results indicate that the course of bortezomib‐induced peripheral neurotoxicity can be severe in subjects with normal neurological examination at baseline, and therefore, careful monitoring during treatment is suggested in these patients.Keywords
This publication has 35 references indexed in Scilit:
- Bortezomib-induced peripheral neurotoxicity: still far from a painless gainHaematologica, 2007
- The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity ScaleJournal of the Peripheral Nervous System, 2007
- Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literatureCancer, 2007
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Quantitative Sensory Findings in Patients With Bortezomib-Induced PainThe Journal of Pain, 2007
- Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicityJournal of the Peripheral Nervous System, 2006
- Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaJournal of Clinical Oncology, 2006
- Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal CancerJournal of Clinical Oncology, 2005
- Toxic neuropathy in patients with pre-existing neuropathyNeurology, 2003
- Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensityCancer, 1992